Immunogenicity and safety of the BBIBP-CorV vaccine in patients with autoimmune inflammatory rheumatic diseases undergoing immunosuppressive therapy in a monocentric cohort.

Batool ZamaniAmin Moradi Hasan-AbadAhmad PiroozmandMahsa DehghaniMaryam ArfaatabarHossein Motedayyen

Published in: Immunity, inflammation and disease (2023)

These findings revealed that the BBIBP-CorV vaccine is effective in the development of neutralizing antibodies in immunosuppressed patients without considerable reactogenicity or induction of disease flares.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
oxidative stress
peritoneal dialysis
multiple sclerosis
prognostic factors
single cell
mesenchymal stem cells
patient reported outcomes
stem cells
dengue virus
zika virus
patient reported